APX 2009
Alternative Names: APX-2009Latest Information Update: 16 Apr 2024
At a glance
- Originator Indiana University School of Medicine
- Developer Ocuphire Pharma
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Angiogenesis inhibitors; APEX1 protein inhibitors; DNA-apurinic apyrimidinic site lyase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic macular oedema; Wet age-related macular degeneration
Most Recent Events
- 31 Dec 2023 Preclinical development in Wet age-related macular degeneration and Diabetic-macular-oedema is ongoing in USA (Intravitreous, Injection)
- 28 Nov 2023 No recent reports of development identified for preclinical development in Diabetic-macular-oedema in USA (Intravitreous, Injection)
- 28 Nov 2023 No recent reports of development identified for preclinical development in Wet age-related macular degeneration in USA (Intravitreous, Injection)